Join our daily newsletter At The Bell to receive exclusive market insights
Argenica Therapeutics (ASX:AGN), a biotech firm focused on the advancement of therapies for brain tissue damage, has initiated dosing for the first acute ischemic stroke (AIS) patient in its Phase 2 clinical trial of ARG007.
“We are absolutely delighted to have officially commenced our Phase 2 clinical trial by dosing our first stroke patient. We will be carefully monitoring the recruitment of patients in this trial, and report progress as we go,” Argenica Managing Director Dr Liz Dallimore said.
“We have engaged an amazing clinical trial team in hospital stroke units across Australia and are looking forward to continuing to work with them throughout the trial.”
The patient, admitted to Royal Melbourne Hospital with suspected Acute ischemic stroke (AIS), met trial criteria and received an intravenous infusion, with the trial’s blinded nature concealing whether ARG007 or placebo was administered.
At present three of the ten participating hospitals—Royal Melbourne Hospital, Princess Alexandra Hospital, and John Hunter Hospital—are operational for patient dosing.
The activation of three additional hospitals—Liverpool Hospital, Royal Adelaide Hospital, and Royal Brisbane Women’s and Children’s Hospital—is expected in the coming weeks, with the remaining four to follow over the next three months, subject to governance approval.
The Phase 2 trial, named SEANCON, aims to assess ARG007’s safety in AIS patients, a crucial step leading up to potential Phase 3 trials and fostering collaborations with global pharmaceutical firms.
News of the trial’s initiation pushed AGN shares up nearly 14% to 67c by midday.
